Single Center, Randomized, Open-label, Cross-over Study to Investigate the Pharmacokinetics of Two Oral Formulations of Elinzanetant After Single Dosing in Healthy Participants
Latest Information Update: 14 Aug 2023
Price :
$35 *
At a glance
- Drugs Elinzanetant (Primary)
- Indications Sex hormone disorders; Vasomotor symptoms
- Focus Pharmacokinetics
- Sponsors Bayer
- 16 Jun 2021 Status changed from recruiting to completed.
- 14 May 2021 Status changed from not yet recruiting to recruiting.
- 19 Apr 2021 New trial record